Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Liabilities and Shareholders Equity: 2017-2023

Historic Liabilities and Shareholders Equity for Solid Biosciences (SLDB) over the last 7 years, with Dec 2023 value amounting to $164.9 million.

  • Solid Biosciences' Liabilities and Shareholders Equity rose 14.67% to $211.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $856.4 million, marking a year-over-year decrease of 2.60%. This contributed to the annual value of $164.9 million for FY2023, which is 36.62% down from last year.
  • Per Solid Biosciences' latest filing, its Liabilities and Shareholders Equity stood at $164.9 million for FY2023, which was down 36.62% from $260.3 million recorded in FY2022.
  • In the past 5 years, Solid Biosciences' Liabilities and Shareholders Equity ranged from a high of $260.3 million in FY2022 and a low of $103.5 million during FY2019.
  • Over the past 3 years, Solid Biosciences' median Liabilities and Shareholders Equity value was $232.4 million (recorded in 2021), while the average stood at $219.2 million.
  • In the last 5 years, Solid Biosciences' Liabilities and Shareholders Equity surged by 65.43% in 2020 and then plummeted by 36.62% in 2023.
  • Solid Biosciences' Liabilities and Shareholders Equity (Yearly) stood at $103.5 million in 2019, then spiked by 65.43% to $171.2 million in 2020, then soared by 35.76% to $232.4 million in 2021, then climbed by 11.99% to $260.3 million in 2022, then plummeted by 36.62% to $164.9 million in 2023.